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Using a mouse model engineered to measure estrogen receptor (ER) transcriptional activity in
living organisms, we investigated the effect of long-term (21 d) hormone replacement on ER
signaling by whole-body in vivo imaging. Estrogens and selective ER modulators were adminis-
tered daily at doses equivalent to those used in humans as calculated by the allometric approach.
As controls, ER activity was measured also in cycling and ovariectomized mice. The study demon-
strated that ER-dependent transcriptional activity oscillated in time, and the frequency and am-
plitude of the transcription pulses was strictly associated with the target tissue and the estrogenic
compound administered. Our results indicate that the spatiotemporal activity of selective ER
modulators is predictive of their structure, demonstrating that the analysis of the effect of estro-
genic compounds on a single surrogatemarker of ER transcriptional activity is sufficient to classify
families of compounds structurally and functionally related. For more than one century, the
measure of drug structure-activity relationships has been based on mathematical equations de-
scribing the interaction of the drug with its biological receptor. The understanding of the multi-
plicity of biological responses induced by the drug-receptor interaction demonstrated the limits of
current approach and the necessity to develop novel concepts for the quantitative analysis of drug
action. Here, a systematic study of spatiotemporal effects is proposed as ameasure of drug efficacy
for the classification of pharmacologically active compounds. The application of thismethodology
is expected to simplify the identification of families of molecules functionally correlated and to
speed up the process of drug discovery. (Molecular Endocrinology 24: 735–744, 2010)
Estrogens are steroidal hormones produced primarilyby the ovaries. Estrogens regulate reproductive func-
tions and control target cell activities in the immune, ner-
vous, cardiovascular, gastrointestinal, and muscle-skele-
tal systems by binding to specific receptors of which two,
estrogen receptor (ER) and ER, have been described.
ERs are ligand-activated transcription factors (TFs), and
there is strong evidence supporting their involvement in
extranuclear signaling (1).
Given the wide range of activities of endogenous estro-
gens during the reproductive years and the significantly
increased risk of cardiovascular, immune, and skeletal
disorders after menopause (2–6), a major effort has been
made to develop hormone replacement therapies aimed at
providing aging women with the same biological advan-
tages observed before cessation of ovarian functions (7–
9). Having observed that the continuous administration
of endogenous female sex hormones was associated with
the risk of undesired hyperproliferation in the reproduc-
tive tissues and that synthetic estrogenic compounds dis-
played tissue-selective agonist/antagonist activity, an
attemptwasmade to develop compounds agonists in non-
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reproductive tissues such as the skeleton and antagonists
(or perhaps more appropriately, neutral compounds) in
the reproductive organs [the so-called selective ER mod-
ulators (SERMs)] (10). Indeed, over two decades of con-
certed effort to develop SERMs has led to the generation
of molecules with limitations in their clinical use despite
the fact that they interact avidly with their intended tar-
get, the ER. The difficulty of identifying estrogenic com-
pounds with the desired profile of activity and safety is
still the object of a large debate in the scientific commu-
nity (2, 7–9). In the attempt to develop a truly specific
SERM, complex comparative studies involving expres-
sion profiling (11, 12), coregulator interactions (13), and
molecular modeling (14) have been applied. These efforts
provided a much deeper insight in our understanding of
ER intracellular physiology and mechanism of action but
minor advancement in the generation of a methodology
able to consistently compare the effects of the synthetic
compounds generated with the activity of endogenous
estrogens in intact, cycling subjects.
A common trait of any methodology that has been
applied to the systematic classification of new molecular
entities is the lack of consideration of the time dimension.
However, it is well known that in each target cell, the
nature and the quality of the transcriptional response to
estrogens is a function of the combinatorial interaction
among at least four very dynamic populations: ligands
(including their pharmacokinetic profile and their metab-
olites), ERs (including isoforms, splice variants, and hetero-
vs. homodimers), ER-modifying enzymes (e.g. kinases,
acetylases, and small-ubiquitin modifying enzymes), and
coregulators (including a panoply of cis- and trans-acting
factors) (1, 15). These populations of factors may change
significantly in response to uninterrupted ligand interac-
tion with the receptor (16), and abundant data demon-
strate that in the case of prolonged exposure to agonists,
intracellular receptors may be subjected to down-regula-
tion (17–20). Furthermore, increasing evidence shows
that the nature of the stimulus responsible for the receptor
transactivation activity may significantly change the dy-
namics of ER interactionwith their responsive elements at
the chromatin level (21). Thus, the time dimension in the
analysis of ER activity is receiving increasing interest.
To test the power of temporal measurements in the
assessment of drug efficacy, we studied the effect of ER
synthetic ligands in a mouse model engineered to obtain
whole-body expression of luciferase in response to ER
activation. Thorough studies demonstrated that in this
mouse, named ERE-Luc, luciferase activity is a faithful
surrogate marker of ER transcriptional activity (22–24).
The main advantage of the use of this model is that lucif-
erase activity can be measured in living animals by quan-
titative analysis of photon emission from selected body
areas (25); this facilitates the study of ER activity in the
time dimension.
Here, the study of ER shows that structurally related
compounds induce unique spatiotemporal profiles of
transcription of the ERE-luciferase surrogate target.
Based on these results, we propose a novel functional
classification of estrogenic compounds thatmay speed the
identification of more efficacious and safer therapies for
the postmenopause and facilitate the comprehension of
the overall effects of endocrine disruptors present in the
environment and alimentary chain.
Results
Longitudinal studies were carried out by administering
the selected compounds for 21 consecutive days to groups
of 5–10 adult female, heterozygous, ERE-Luc reporter
mice with C57/BL6J background. Three weeks before ini-
tial SERM dosing, mice were ovariectomized (OVX) to
eliminate circulating estrogens as a surrogate model of
menopause.We also studied age-matched, cycling (intact)
female mice as a positive control for the hormonal re-
placement studies. Mice were treated in the morning
(0900 h) at the following daily concentrations: 17-estra-
diol (E2), 6 g/kgd sc pellet (scp); conjugated estrogens
(CE, Premarin), 3 mg/kg per os; bazedoxifene (BZA), 10
mg/kg per os; lasofoxifene (LAS), 50 g/kg scp; os-
pemifene (OSP), 2 mg/kg scp; raloxifene (RAL), low 2
mg/kg and high 10 mg/kg per os and scp; and tamoxifen
(TAM), 0.8 mg/kg scp. During the chronic study, photon
emissionwasmeasured in selected body areas bymeans of
a segmentation algorithm previously described (25) once
a day (at 1500 h) (Supplemental Fig. 1 published on The
Endocrine Society’s Journals Online web site at http://
mend.endojournals.org). At the end of the study, we plot-
ted the photon emissionmeasured daily in each animal vs.
time (Supplemental Figs. 2–6). In the body areas studied,
each compound had a different profile of activity as better
exemplified for the skeletal, hepatic and genital area after
treatment with E2 and LAS in Fig. 1, A–C. In the skeletal
and genital areas of mice treated with E2, luciferase ac-
tivity was found to increase with time of exposure; in
contrast, in the hepatic area, photon emission increased
rapidly after E2 administration and decreased over time.
LAS resulted in little to no change in the hepatic and
skeletal areas, but in the genital area, photon emission
became higher than in controls toward the end of the
treatment interval. In the OVX mice, in all anatomical
areas taken in consideration, ER activity did not change
noticeably during the treatment. The analysis of the sig-
nals in each animal showed that photon emission fluctu-
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ated over consecutive days of exposure in all mice studied,
including the OVX. Further in-depth analysis of the bio-
luminescence profile in time showed that with some of the
drugs, this oscillatory trend appeared to have a fixed am-
plitude and frequency (e.g. LAS in the genital area) (Fig.
1C). By comparing the effects of the different treatments
in each experimental group, we concluded that such an
oscillation was a characteristic response to the specific
ligand in the various tissues examined (Supplemental
Figs. 2–6).
To establish that the oscillatory pathway was not due
to imaging artifacts, we measured photon emission from
the hepatic and genital areas in a group of vehicle- and
E2-treated OVX ERE-Luc mice for several days. Mice
were then euthanized when bioluminescence was highest
or lowest (Fig. 1, D and E). Enzymatic quantitative anal-
ysis of luciferase activity in tissue extracts proved that the
changes in bioluminescence reflected a differential accu-
mulation of the enzyme in time in liver (Fig. 1F) and in
vagina (not shown). To investigate whether the pulses
of photon emission were induced by
changes of circulating ER ligands, we
measured E2 in plasma. We found se-
rum levels of E2 to be identical in ani-
mals euthanized at the phases of high
or low photon emission (Fig. 1G). In
line with this observation, the uterus
weight did not change in relation to the
state of ER transcriptional activity but
was clearly responsive to OVX and E2
treatment (Fig. 1H). Thus, the changes
in bioluminescence clearly reflected
changes in luciferase content in the tis-
sues and were unlikely to be caused by
fluctuations of ligands in the blood-
stream. Next we tested whether the os-
cillations of photon emissionwere pro-
duced by ligand-dependent changes in
the expression of ERs (4–6). Figure 1I
shows that in liver, ER contentwas sta-
ble in time and not regulated by OVX
or prolonged treatment with E2.
Having established that the fluctua-
tions in photon emission were likely to
reflect changes in the ability of the
ligand-ER complex to interact with
the transcriptional apparatus, we con-
cluded that the quantitative analysis of
such oscillatory behavior might have
provided an insight on the pharmaco-
logical efficacy of each drug. Thus, we
further studied the curves relative to
luciferase-induced activity in the 21 d
of observation. Using differential calculus (local maxima
analysis), we counted the number of peaks of luciferase
activity induced by each treatment in the 21-d timeframe.
The amplitude and frequency of each cycle was measured
by spectral analysis. Figure 2 shows exemplificative re-
sults obtained in two of the body areas where photon
emission had been studied: genital and skeletal tissues. In
intact cycling females, the number and amplitude of the
peaks displayed was higher than in OVX females, con-
firming that ER transcriptional activity is reduced with
estrogen deficiency (e.g. postmenopause). Interestingly,
several compounds, including LAS, CE, BZA, and CE
plus BZA increased significantly the numbers of peaks in
the skeletal but not in the genital area (Fig. 2A). Con-
versely, quite sensitive to the treatments was the ampli-
tude of the cycles in the genital areas, as shown by the
significant enhancement induced by E2, TAM, and CE
(Fig. 2B). The 4-d periodicity of the cycles observed in
the cycling animals was conserved in most treatments
FIG. 1. Uninterrupted drug administration induces discontinuous reporter accumulation.
Profile of photon emission in 21 d in skeletal (A), hepatic (B), and genital (C) areas of single,
representative, OVX ERE-Luc mice after treatment with vehicle (veh), E2, or LAS. Drugs were
administered via a dorsal implant of a continuous-release pellet delivering the compounds at a
fixed concentration. Photon emission in discrete body regions was segmented in a Matlab
environment using an algorithm previously described (25) and defined as the number of
counts per second per centimeter square (cts/cm2s) corrected for instrument efficiency. In a
parallel experiment, photon emission was measured daily in individual animals treated with
vehicle (veh) or E2; groups of six mice were euthanized at the high (H) or low (L) photon
emission (D and E), blood was collected, and uterus and liver tissues were dissected. F,
Luciferase enzymatic activity in liver tissue extracts. G, E2 content was measured in samples of
plasma pooled from two mice using gas chromatography mass spectrometry (see Materials
and Methods). The analysis was done in duplicate on a total of three samples for each
experimental condition. H, Weight of uterus frozen tissue. Bars represent mean  SEM (n  6).
*, P  0.043 (D); *, P  0.043 (E); **, P  0.002 (F); **, P  0.003 (H) (ANOVA followed by
Bonferroni). I, ER protein content as measured by Western blot in liver tissue extracts (n  6).
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(surprisingly also in OVX mice). The only exception
found was in the skeletal area where LAS decreased the
frequency of the pulses to about 6 d (Fig. 2C).
Next, to measure the overall effect of the treatment
over time in each animal, we calculated the area under the
curve (AUC) relative to the 21 d treatment (Fig. 2D). In
cycling mice, the AUCwas significantly higher than in the
OVX animals in both the genital and skeletal tissue com-
partments. As expected, E2 and CE significantly in-
creased the AUC in the genital area. Interestingly, E2
failed to affect the AUC in the skeletal area where CE and
CE plus BZA where active. In this site, RAL was able to
increase photon emission significantly, however, only at
the higher dose, which is known to protect against resorp-
tive bone loss (26). Finally, to evaluate the potency of the
effect of each drug at the dosage selected for the 21-d
study, the ER ligands were administered to groups of six
OVX females at time 0, and photon emission was mea-
sured at 0, 3, 6, 16, and 24 h after treatment (data not
shown). In line with previous observations made in our
laboratory (22–23), the highest photon emission was ob-
served at the 6-h time point in all body areas. The amount
of luciferase produced at 6 h was therefore selected as a
measurement of the potency of each drug in acute treat-
ment. Figure 2E shows photon emission in the genital and
skeletal areas at 6 h. Photon emission in cycling mice was
measured at the highest point of its oscillation in each
organ; thus, bioluminescence was found to be signifi-
cantly higher than in OVX mice in both areas. With re-
gard to the different treatments, at the dosage used, only
OSP and E2 significantly increased ER activity in the gen-
ital area, whereas in the skeleton, increased biolumines-
cence was seen only with E2 and CE.
As clearly indicated in Fig. 2, the parameters, namely
descriptors, used to measure ER transcriptional activity
spatiotemporally were modulated differently by each of
the ER ligands. Thus, we askedwhether the set of descrip-
tors identified were necessary and sufficient to provide a
quantitative assessment of the pharmacological efficacy
of the drug tested. First, we verified that the drug property
described by each parameter was independent from the
others; this was achieved by direct comparison of the
parameters in pairs and measuring their coefficient of
correlation (Pearson’s R2). Eighty percent of the R2 values
indicated a significant lack of correlation among the de-
scriptors selected. The low coefficient of correlation
found for all pairs (Fig. 3) indicated that each of the pa-
rameters selected described a unique feature of the drug
effect and therefore was suitable to be used in a clustering
algorithm aimed at verifying the extent to which drugs
behave differently or similarly with each other. More im-
portantly, by comparing these sets of parameters of drug-
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FIG. 2. Comparative analysis of the effect of treatment with selected
SERMs on luciferase accumulation in skeletal and genital areas of ERE-Luc
OVX mice. A–D, OVX females ERE-Luc mice were treated daily with 6 g/
kg sc E2, 3 mg/kg per os CE, 10 mg/kg per os BZA, 50 g/kg sc LAS, 2
mg/kg sc OSP, 2 or 10 mg/kg per os RAL, or 0.8 mg/kg per os TAM.
Photon emission measured in individual ERE-Luc mice was plotted against
time (21 d). Bars represent the mean SEM of a minimum of five animals
per group. A, Peak number. Data were scored from the second-derivative
plot using GraphPad Prism. On the basis of the variability of photon
counting (coefficient of variation 12%), peaks less than the 15% of the
distance between the minimum and the maximum are ignored [*, cycling
(cyc) P 0.023; LAS P 0.004; CE P 0.021; BZA P 0.036; BZACE
P 0.028]. B, Peak amplitude. Photon emission was centered on the
y-axis by the first derivative, and photon emission rates were then
processed by fast Fourier transformation into its component sine waves
with a 64 zero padding. Analyzed spectra were windowed at bins 3 and
10. The amplitude, estimating the degree of displacement from the
resting state, was calculated as the square root of the 95th percentile of
the power spectra (*, cyc P 0.002; E2 P 0.001; TAM P 0.011; CE
P 0.003). C, Peak period. Periodicity is estimated by the inverse of the
frequencies under the amplitude previously calculated (*, LAS P 0.019).
D, AUC. The AUC of the plot of photon emission in the 21 d treatment
was calculated using GraphPad Prism by a trapezoidal approximation
(*, genital area cyc P 0.012, E2 P 0.001, and CE P 0.004; skeletal
area cyc P 0.001, E2 P 0.001, and BZA P 0.002). E, Groups of six
ERE-Luc OVX mice were treated as in A, and photon emission in individual
areas was measured 6 h after drug administration (*, genital area cyc P
0.021, OSP P 0.038, and E2 P 0.017; skeletal area cyc P 0.020, E2
P 0.008, and CE P 0.013). Bars represent mean SEM (n 6).
Statistical analysis was done with ANOVA followed by Bonferroni
comparing the effect of each experimental group with OVX and cycling
mice.
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treated mice with those found in OVX or cycling animals,
we were able to have a measure of how much each drug
was effective in replacing the endogenous hormones and
thus constituted the best replacement therapy.
Drug classification was obtained using clustering anal-
ysis (27). For each anatomical area, a dissimilarity matrix
based on Manhattan distances between descriptors was
analyzed. The resulting dendrograms grouped SERMs ac-
cording to their relative similarities in biological activity.
Most interestingly, Fig. 4 shows the large Manhattan dis-
tance of both genital (Fig. 4A) and skeletal (Fig. 4B) areas
in OVX and cycling females. This was also observed in
the other body areas such as tail, abdomen, and thymus
(data not shown) and indicates that these two biological
conditions represent two extremes for ER activity on the
ERE-Luc reporter gene. As expected, the compounds
studied grouped differentially in the two body areas. In
the genital area RAL and BZA, two well-described antag-
onists of ER in uterus (28, 29), clustered with OVXmice,
whereas CE was found very close to cycling animals.
However, when CE was administered in association with
BZA, the combination therapy moved into the OVX clus-
ter. OSP and LAS, two SERMs known to have an activity
on vaginal atrophy (30, 31), emerged as basal branches in
the OVX cluster. Unlike CE, E2 did not group with cy-
cling mice, possibly indicating that the mixture of estro-
genic compounds in CE are able to better mimic the state
of ER activation during the estrous cycle (32). A different
picture was obtained by the cluster analysis in the areas
representative of the skeletal tissue where CE, BZA, and
RAL (only at the higher dosage) were found to groupwith
cycling animals (9). E2 and LAS emerged closer to (but
still rather distant from) OVX animals (33), although the
closest neighbors of the OVX mice were TAM (34) and a
subcluster containingOSP and low-dose RAL. These data
led us to conclude that the descriptors used to define the
efficacy of drug action in the different tissues provided a
view of the activity of the compounds used in this study
that were in line with our current knowledge of their
biological action.
To further challenge the ability of the method to clas-
sify drugs on the basis of their spatiotemporal activity, we
used all the descriptors identifying the effect of SERMs on
ER in the different ERE-Luc anatomical areas (genital,
skeletal, hepatic, abdominal, and thymic) to create a sin-
gle phenogram. This analysis, by containing the features
of drug action in time in different organs, may be consid-
ered a multivariate fingerprint of drug efficacy. Figure 4C
shows that the analysis of the biological data describing
the activity of E2, BAZ, RAL, LAS, OSP, and TAM led to
clusters of compounds very related from the structural
point of view, thus demonstrating that the detailed anal-
ysis of the effects of the different treatments in space and
time carried out by us on a single surrogate marker was
sufficient to group compounds belonging to the same
chemical family, thus proving the unique strength of the
methodology applied here.
Discussion
The present study provides the first demonstration that in
living organisms subjected to long-term stimulation with
natural and synthetic ligands, ER-mediated transcrip-
tional activity oscillates with pulses of a frequency and
amplitude of the transcription pulses that is strictly asso-
ciated with the type of estrogenic compound adminis-
tered, its dosage, and the organ investigated. The accurate
spatiotemporal measurement of such oscillations also in
comparison with OVX and cycling mice provides a
unique and novel methodology to measure drug efficacy.
It is now well accepted that transcriptional regulation
by nuclear receptors is a dynamic and cyclical process
(35). Biochemical analysis (chromatin immunoprecipita-
tion and nuclear run-on) as well as molecular imaging in
living cells demonstrated significant oscillations in tran-
scription mediated by inducible TFs such as ER (36),
androgen receptor (37), glucocorticoid receptor (35),
or nuclear factor-B (38). Depending on the mechanism
involved in the phenomenon, TF-dependent transcription
oscillates in a timeframe of seconds, minutes, or hours
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drug activity. A, Correlation analysis was done for each pair of
descriptors to verify the degree of redundancy of the parameters
selected for the clustering analysis; B, degree of correlation in each pair
of drug activity descriptors as measured by Pearson’s R2.
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(39). Initial chromatin immunoprecipitation studies
showed that upon E2 stimulation, the levels of ER and its
coregulator at the promoter of target genes can cycle with
20- to 40-min intervals (36); these observations were sup-
ported by nuclear run-on assay on selected endogenous
target genes that expanded the phase of the pulse to up to
2 h. In vivo imaging studies based on fluorescence recov-
ery after photobleaching enabled to visualize ER dynamic
activity at the chromatin level and demonstrate dissimilar
pulses upon ER stimulation with natural or synthetic li-
gands (40). Specific mechanisms have been recognized to
explain the dynamics of oscillation described by studies
at the cellular level (35, 39). These include 1) shuttling
of the TF between nucleus and cytoplasm; 2) complex
interactions between multiple activating regulatory
proteins, OVX, and the chromatin template at the pro-
moter of target genes; and 3) fluctuation of the stimu-
lating effector.
Here we report that in response to a continuous stim-
ulus induced by natural and synthetic ER ligands, the
oscillations of ER-induced transcriptional activity have a
timeframe of days. We tested several hypotheses made to
explain the mechanism of daily pulsatility. First, we ruled
out the hypothesis of a discontinuous presence of the
stimulating ligands because E2 plasma concentration and
uterine weight (the classical estrogenic bioassay) were
both found unchanged at a low or high level of luciferase
transcription. Indeed, the same conclusion had been sug-
gested by the observation that in each animal, not all
organs cycled synchronously and with the same fre-
quency. Furthermore, the periodicity of oscillation was
independent of the half-life of each ligand (e.g. BAZ and
RAL have a half-life in mouse of 2–4 h, yet the period of
oscillation was about 4 d in uterus like LAS (Komm, B.,
personal communication), which has a half-life in mouse
of about 7 d (Komm, B., personal communication).
Next, we considered the possibility of changes in ER
protein content. Previous studies have shown that ER
protein is decreased after ligand stimulation (17–21), al-
though ER turnover is quite rapid (3–5 h); thus, the levels
of ER may be quickly replenished. This notion played
against cycles of pulses in a timeframe of days. Further-
more, a protective mechanism against loss of hormone
responsiveness was described during continuous stimula-
FIG. 4. Phenetics of drug action. Each descriptor (peak number, amplitude, period, AUC, and drug potency) was normalized on the average
calculated on intact cycling (cyc) females (considered equal to 100). A matrix was built for each anatomical area: each column contains one
descriptor, and each cell contains the descriptor averages for each experimental group. Agglomerative hierarchical clustering (27) was computed
with a Manhattan metric and a complete linkage method with an R code available online (Agglomerative Nesting version 1.0.2, Office for
Research Development and Education; http://www.wessa.net/). In the dendrogram, distances between branch lengths represents the distance of
the menopause model (OVX) vs. the physiology model (cyc); hormone replacement efficacy is measured by its ability to mimic ER activity in the
cycling mice. A and B, SERM classification (hierarchical clustering) in the genital area (A) and in skeletal area (B); C, multidimensional imaging
descriptors from all anatomical areas measured (genital, skeletal, hepatic, abdominal, and thymic) are clustered as above; dendrogram branches
group families of structurally related compounds.
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tion whereby ER protein is stabilized due first to a de-
creased rate of proteolysis and second to the accumula-
tion of proteasome-resistant, phosphorylated form of
receptor (41, 42). In keeping with this observation, we
found the same content of ERs at both phases of high or
low transcriptional activity when we measured ER con-
tent in liver stimulated with E2. Finally, we discarded the
hypothesis of transcriptional pulses generated by changes
in the ratio or interaction between the two ER receptors,
ER and ER, because the transcription pulses were ob-
served also in liver, an organ that expresses only ER (43
and data not shown).
Thus, the cause and the mechanism responsible for the
oscillations here described remains to be elucidated in
molecular terms, but we believe that the dynamics of ER
transcriptional activity are very relevant from the physi-
ological point of view and need to be reproduced faith-
fully in hormone replacement therapy. It has been long
known that pulsatility represents a common mechanism
for most hormones acting through intracellular as well as
membrane receptors. Hormones such as gonadotropins
or GH fail to exert their physiological effects if not ad-
ministered with the correct rhythmicity, and ultradian
hormone stimulation is essential to induce a truthful tran-
scriptional response to GR stimulation (44). Endogenous
estrogens are released as a result of activity of highly
regulated and dynamic connections in the hypothalamic-
pituitary-gonadal axis. The temporal activity of the hy-
pothalamic-pituitary-gonadal axis is set to ensure a well-
controlled gene expression, necessary to maintain all the
physiological functions of estrogens in reproductive and
nonreproductive organs. Thus, to maximize the efficacy
of hormone replacement therapies, we should identify
ligands that can closely mimic the temporal effects of
endogenous hormones. Clustering compounds on the
bases of their effects in space and time on ER transcrip-
tional activity and assessing the extent to which the phar-
macological treatment overcomes the effect of ovariec-
tomy and mimics the activity of ER in cycling mice may
open the way to the identification of an efficacious and
safe treatment for the postmenopause. Furthermore, clas-
sifying alimentary and environmental endocrine disrupt-
ers and comparing their activity to well-studied com-
pounds may facilitate the understanding of their real
toxicity.
The results of the clustering analysis in the genital area
are in line with data presented in clinical and preclinical
literature and underline the known activity of TAM (9),
OSP (30), and LAS (31) in the vagina. More puzzling are
the results in bone where TAM was found to group with
OVXmice. Indeed TAMhas never been prescribed for the
prevention of osteoporosis in women due to the observa-
tion that it caused loss of bone mineral density in pre-
menopausal women (34); however, additional studies in
postmenopausal women showed protective activity of
TAM in bone (9). These findings indicate a complexity of
action of SERMs in bone that awaits further experimental
explanation.
We believe that the relevance of the present study goes
far beyond the field of estrogen action. The methodology
here developed that enables the classification of molecu-
lar entities on the basis of their actions in the four dimen-
sions (thus including the time dimension) may represent
the highly needed, novel, paradigm to measure drug effi-
cacy. Drug classification is currently based on principles
set at the beginning of the last century. In fact, it dates at
that time the introduction of the drug-receptor interac-
tion theory that enabled the measurement of the ability of
a given molecule to interact with its receptor (namely
affinity) and to induce biological effects (efficacy) (45–
47). Drug efficacy, originally evaluated in organ cultures,
is now generally characterized in cell cultures. However,
the present understanding of the plasticity and promiscu-
ity of intracellular signaling pathways highlighted the cur-
rent limitations to provide an unambiguous classification
of drug efficacy (48–50) and the necessity to find novel,
more efficacious ways to compare families of molecular
entities. The best example of the difficulties in categoriz-
ing biologically active compounds was provided by ER
ligands (51, 52). Compounds such as TAM,RAL, or BZA
were described to either block or induce ER transcrip-
tional activity depending on the target tissue or gene un-
der consideration (53, 54), and a novel terminology was
introduced (SERMs) in an attempt to differentiate these
molecules from other estrogens. Yet, when studying
SERM effects in a single target cell, each of these mole-
cules may be redefined as an ER agonist or antagonist
dependent upon the signaling pathway considered. This
lack of a definite method to classify drug actions is com-
mon to all classes of drugs and is considered as a major
obstacle in drug development (55).
A well-known feature in drug action is the transforma-
tion of its pharmacological effect with time due to the
mechanisms of defense that each organism has against
xenobiotics. As a consequence, drug efficacy should be
evaluated in different organs and at different times. The
use of reporter animals offers for the first time the oppor-
tunity to measure drug effects spatiotemporally, opening
the way to the generation of novel methods to classify
drugs. In addition, the study of drug effects on a well-
defined target facilitates the assessment the efficacy of the
treatment in models of disease and the direct comparison
of the effect of the drug with the physiological, healthy
status. In our view, the present study provides compelling
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evidence for the power of longitudinal imaging and an-
ticipates the possibility of a reverse approach in medicinal
chemistry where the spatiotemporal measurement of an
intended target drives the classification of chemically re-
lated compounds.
Materials and Methods
Experimental animals
All animal experimentation was carried out in accordance
with European guidelines for animal care and use of experimen-
tal animals, approved by the Italian Ministry of Research and
University, and controlled by the panel of experts of the Depart-
ment of Pharmacological Sciences, University of Milan.
Compounds tested
E2, RAL, and TAM were purchased from Sigma-Aldrich
(Pomezia, Italy); EC and BAZ were from Wyeth (Collegville,
PA); and LAS andOSPwere fromHormosMedical Ltd. (Turku,
Finland). Compounds were administered at doses equivalent to
those used in humans as calculated by the allometric approach
and further harmonized with the companies that developed the
drugs to be closer to their previous preclinical data. All control
groups (OVX) received vehicles.
In vivo imaging
Raw bioluminescence was measured with tiff images of
512 512 pixels at 16 bits. Each pixel contained the number of
counts detected over the exposure period of 5 min at the reso-
lution of about 0.3 pixels/mm. Background was estimated on
the average of 10 background acquisitions and arithmetically
subtracted from the raw images. Before each imaging session,
instrumental efficiency wasmeasured with an external source of
photons (Glowell, Lux Biotechnology, Edinburgh, UK). Ana-
tomical areas (limb and tail/skeletal, genital, hepatic, abdomi-
nal, and thymic) were segmented in aMatlab environment using
an algorithm previously described. In each anatomical area,
photon emission was defined as the number of counts per sec-
ond per centimeter squared corrected for instrument efficiency.
All the measurements were in the linearity range of the detector
(IVIS Lumina; Caliper Life Sciences, Hopkinton, MA).
Quantitative analysis of plasma E2
Steroids were extracted according to Caruso et al. (56) with
minor modification. Briefly, the deuterated internal standard
2,4,16,16-D4-17-estradiol (D4-17-E; CDN Isotope, Pointe-
Claire, Quebec, Canada) was added to 100–200 l plasma.
After addition of acetic acid (1% in methanol), samples were
loaded onto C18 cartridges (Discovery DSC-18, 500 mg;
Supelco, Milano, Italy). The steroid fraction was eluted with
methanol (5 ml), and the organic residue was reconstituted with
methanol/water (1:1) before the injection in a RP-C18 analytical
column (Hypersil GOLD; Thermo Fisher Scientific Inc.,
Rodano, Italy; 3 m, 100 mm  3 mm inner diameter). The
HPLC (Surveyor LC Pump Plus; Thermo Fisher Scientific Co.,
Waltham, MA) was coupled to a linear ion trap mass spectrom-
eter (LTQ; Fisher Scientific) equippedwith an atmospheric pres-
sure chemical ionization source operating in the positive ion
mode. E2 was identified on the basis of both the retention time
and the tandem mass spectrometry spectrum of reference com-
pounds. The quantitative analyses were done monitoring spe-
cific ions (selected ion chromatogrammode) in the tandemmass
spectrometry spectrum obtained by collision of precursor ion in
the mass spectrometry spectrum (56) using calibration curves
generated with deuterium-labeled internal standards.
Western analysis
Was carried out Western analysis as previously described.
Briefly, after quantification of the proteins in whole-cell ex-
tracts, 28 g cell protein was loaded onto discontinuous gradi-
ent SDS-PAGE (10–5%) gels. After electrophoresis, proteins
were transferred to nitrocellulose membrane and incubated first
with the primary antibodies (all 1:1000) overnight and then
with the peroxidase-conjugated secondary antibody (Bio-Rad,
Hercules, CA) for 1 h. Proteins were detected by chemilumines-
cence (Amersham Biosciences, Arlington Heights, IL).
Statistical analysis
P values were calculated with one-way ANOVA followed by
Bonferroni post hoc test with GraphPad Prism version 5.02 for
Windows (GraphPad Software, San Diego, CA).
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